Advancing cardio-oncology: precision-guided cardiovascular care for oncology patients

Cardio-oncology, an emerging subspecialty at the intersection of cardiology and oncology, addresses the growing cardiovascular burden among cancer patients and survivors. Advances in cancer therapies, including anthracyclines, immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, and targeted tyrosine kinase inhibitors (TKIs), have improved survival but also introduced diverse cardiovascular complications such as heart failure, arrhythmias, hypertension, and ischemia. These complications are influenced by traditional cardiovascular risk factors, aging, and comorbidities, underscoring the need for precision-guided risk assessment and management. Recent innovations in cardio-oncology focus on personalized risk stratification using clinical risk models, genetic profiling, and emerging biomarkers such as high-sensitivity troponin, natriuretic peptides, and microRNAs. Advanced imaging modalities, including echocardiography, global longitudinal strain analysis, and cardiac magnetic resonance, are central to early detection of subclinical injury, with artificial intelligence (AI) increasingly enabling real-time, individualized surveillance. The integration of novel biological insights, such as clonal hematopoiesis of indeterminate potential, further refines risk prediction and mechanistic understanding. Effective cardio-oncology care requires proactive, multidisciplinary strategies that span the continuum from treatment initiation to survivorship, emphasizing longitudinal monitoring, cardioprotective interventions, and patient-centered care. Despite progress, challenges remain in standardizing predictive models, validating biomarkers, and ensuring equitable access to specialized services. Looking forward, the convergence of AI-driven imaging, multi-omic data, and precision therapeutics promises to transform cardio-oncology from reactive management to proactive, personalized care, optimizing both cancer outcomes and long-term cardiovascular health.

Authors

Institutions

Publication Details

Journal
Cardiology Plus
Published
2025-10-01
DOI
https://doi.org/10.1097/cp9.0000000000000142
Citations
2
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
2.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Advancing cardio-oncology: precision-guided cardiovascular care for oncology patients

J. E. Liu
2 citations
Cardiology Plus
Chemotherapy-induced cardiotoxicity and mitigation
2.78
article

Advancing cardio-oncology: precision-guided cardiovascular care for oncology patients

J. E. Liu
article en
2 citations

Abstract

Cardio-oncology, an emerging subspecialty at the intersection of cardiology and oncology, addresses the growing cardiovascular burden among cancer patients and survivors. Advances in cancer therapies, including anthracyclines, immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, and targeted tyrosine kinase inhibitors (TKIs), have improved survival but also introduced diverse cardiovascular complications such as heart failure, arrhythmias, hypertension, and ischemia. These complications are influenced by traditional cardiovascular risk factors, aging, and comorbidities, underscoring the need for precision-guided risk assessment and management. Recent innovations in cardio-oncology focus on personalized risk stratification using clinical risk models, genetic profiling, and emerging biomarkers such as high-sensitivity troponin, natriuretic peptides, and microRNAs. Advanced imaging modalities, including echocardiography, global longitudinal strain analysis, and cardiac magnetic resonance, are central to early detection of subclinical injury, with artificial intelligence (AI) increasingly enabling real-time, individualized surveillance. The integration of novel biological insights, such as clonal hematopoiesis of indeterminate potential, further refines risk prediction and mechanistic understanding. Effective cardio-oncology care requires proactive, multidisciplinary strategies that span the continuum from treatment initiation to survivorship, emphasizing longitudinal monitoring, cardioprotective interventions, and patient-centered care. Despite progress, challenges remain in standardizing predictive models, validating biomarkers, and ensuring equitable access to specialized services. Looking forward, the convergence of AI-driven imaging, multi-omic data, and precision therapeutics promises to transform cardio-oncology from reactive management to proactive, personalized care, optimizing both cancer outcomes and long-term cardiovascular health.

Cardiology PlusVol. 10(4)
Memorial Sloan Kettering Cancer Center (US)
Good health and well-being
Openalex Percentile: Top 7%
Chemotherapy-induced cardiotoxicity and mitigation
2.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Advancing cardio-oncology: precision-guided cardiovascular care for oncology patients — J. E. Liu · Cardiology Plus (2025) | TGRS Research Map | TGRS